10月9日 - ** Bluejay Diagnostics公司BJDX.O的股价在盘前交易中翻了一番多，达到4.72美元。
** 该公司称已扩大了与日本三洋精工的合作，以帮助其用于败血症管理的新型Symphony快速检测平台实现商业化
** 据美国国立卫生研究院（NIH）称，败血症是由人体对感染的反应引起的一种危及生命的疾病。
** BJDX的Symphony平台旨在20分钟内提供IL-6的检测结果，IL-6是一种与败血症中的炎症有关的蛋白质。
** 公司称Symphony仍在等待美国FDA的批准
** 截至上次收盘，该公司股价年累计下跌约 62
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.